March 1, 2017 @ 5:53 am By Erin Hobey  |  

Valued at 9,400,000€, Bionure is overfunding on Capital Cell, raising more than 975,422€ from over 210 investors for 9.27% equity for its neuroprotector and myelin regenerator drug which treat Multiple Sclerosis. Bionure is a biotech-based company that is developing a new drug for the treatment of multiple sclerosis, a… Read More